Shares of Wockhardt Ltd skyrocketed 9% on 3 January after the Indian pharma authority approved an oral antibiotic for the treatment of pneumonia.

The Central Drugs Standard Control Organization (CDSCO) has authorized the antibiotic Nafithromycin, which is sold under the brand name Miqnaf, as a new treatment for adult community-acquired bacterial pneumonia (CABP). Additionally, multidrug-resistant (MDR) bacterial pneumonia is treated. Miqnaf, taught by Wockhardt, is a relatively short course that is taken once a day for three days.

Following permission, Wockhardt said it plans to launch Miqnaf into the Indian market in the following months.

Antibiotic resistance is a severe issue in India, and it also impacts incidences of community pneumonia (CABP). According to Wockhardt, miqnaf’s capacity to treat respiratory infections across the population makes it a good monotherapy option for CABP. Wockhardt claims that for more than 15 years, Miqnaf has been the focus of a large number of clinical and non-clinical studies, including human trials conducted in the US, Europe, South Africa, and India.

In its filing, the company said, “the ultra-short course regimen enhances the patients’ compliance to treatment resulting in favourable outcome.”

Wockhardt says that because amoxicillin does not cover atypical medications and azithromycin and other oral antibiotics ‘have severe resistance difficulties,’ patients often need to be hospitalized and receive intravenous treatment. Miqnaf’s purpose, according to Wockhardt, is to “obviate the need of such hospitalization.”

CABP affects millions of individuals worldwide, but 23% of the disease’s cases occur in India.

At 11:39 am, the shares of Wockhardt were trading 6.23% higher at Rs 1,536.50 on NSE.

Feeling overwhelmed by the markets? Let Unicorn Signals be your guide. Our user-friendly app simplifies complex data and provides actionable trading signals. Download the app today and trade with confidence!